General aging (40+)
Whole-system aging — declining mitochondrial function, telomere shortening, sarcopenia, slowed recovery, gradual cognitive shifts.
GLP-1/GIP metabolic foundation + GH-axis lean-mass layer · 3 phases · guided multi-peptide program with decision criteria and add-to-stack handoff.
mTOR pulse + NAD+ substrate + senolytic layer · 3 phases · guided multi-peptide program with decision criteria and add-to-stack handoff.
Topical + systemic collagen / aesthetic layer · 3 phases · guided multi-peptide program with decision criteria and add-to-stack handoff.
Thymic + antioxidant + antimicrobial peptide stack · 2 phases · guided multi-peptide program with decision criteria and add-to-stack handoff.
Mucosal-repair + anti-inflammatory stack · 3 phases · guided multi-peptide program with decision criteria and add-to-stack handoff.
Anxiolytic + neurotrophic peptide stack · 2 phases · guided multi-peptide program with decision criteria and add-to-stack handoff.
What changes during this transition
The peptide categories most directly relevant to aging biology: mitochondrial-targeted (SS-31, MOTS-c) for energy metabolism and oxidative damage, longevity-axis (epithalon for telomere support — Russian literature only), senolytic candidates (foxo4-DRI), GH-axis for lean mass and recovery (CJC-1295, ipamorelin, tesamorelin), and NAD+ precursors (NMN, nicotinamide-riboside) for cellular energy. Evidence quality varies widely — mitochondrial peptides are Tier 3 in humans, NAD precursors Tier 2 for some endpoints, epithalon Tier 3 (Russian-only). Editorial honesty matters: aging interventions are full of overconfident claims; the library calls out evidence tiers per peptide.
Important caveat
Lifestyle (sleep, exercise, diet, stress) outranks any peptide for aging outcomes. Lab monitoring matters more than peptide selection — track IGF-1, fasting insulin, HbA1c, lipids (incl. ApoB), inflammatory markers (hs-CRP), and over time, body composition + DEXA-scan trends.
Peptides editorially relevant to general aging (40+)
12 peptides from the library — each evidence-tiered honestly.
- SS-31 (Elamipretide)Tier 2
Mitochondrial-targeted peptide
Mitochondrial-targeted peptide. FDA-approved for Barth syndrome (2024); explored in other mitochondrial conditions and as a longevity compound.
- MOTS-cTier 3
Mitochondrial-derived peptide
Mitochondrial-encoded peptide with strong rodent data on insulin sensitivity, endurance, and metabolic health.
- EpithalonTier 4
Synthetic tetrapeptide (AEDG)
Synthetic tetrapeptide claimed to extend telomere length and reduce all-cause mortality in older adults.
- FOXO4-DRITier 4
Senolytic peptide (preclinical)
Senolytic peptide designed to selectively kill aged cells. Mouse data only — no published human trials.
- CJC-1295Tier 3
GHRH analog
Long-acting GHRH analog often paired with a GHRP. Strong PK data in humans; outcome data is limited.
- IpamorelinTier 3
GHRP / ghrelin mimetic
Selective GH-releasing peptide with minimal cortisol or prolactin elevation in early studies. Human outcome evidence is limited.
- TesamorelinTier 1
GHRH analog
FDA-approved for HIV-associated lipodystrophy. Off-label use for general fat loss is meaningfully less supported.
- NMNTier 3
NAD+ precursor
Oral NAD+ precursor with growing — but contested — human data. Bioavailability is the unresolved question: oral NMN is largely converted to NR before it reaches cells.
- Nicotinamide Riboside (NR)Tier 2
NAD+ precursor
Oral NAD+ precursor with consistent evidence that it raises blood NAD+ in humans — but underwhelming evidence that the NAD+ rise translates to clinical outcomes outside specific populations.
- NAD+Tier 3
Coenzyme
Coenzyme central to redox biology, marketed as IV / SubQ / oral and via NMN/NR precursors. Most clinical claims rest on weak or contested evidence; bioavailability is a real, unresolved question.
- RapamycinTier 1
mTOR inhibitor
Approved immunosuppressant for transplant; the canonical mTOR inhibitor. Off-label longevity dosing (5–8 mg weekly) is widely community-practiced; PEARL Phase 2 (2024) is the largest healthy-adult RCT and was equivocal.
- 5-Amino-1MQTier 3
NNMT inhibitor (small molecule)
Small-molecule NNMT inhibitor with intriguing mouse-adipocyte data. Almost no human evidence. Tier 3/4. Marketed for fat loss far ahead of the data.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.